LungVision Enables Diagnosis and Treatment of 12mm Ground-Glass Opacity (GGO) in Single-Anesthesia Event
LungVision + Ethicon Monarch Robot - September 13, 2023

Lesion Characteristics

Lesion Size (diameter): 12mm GGO (5mm Solid /12mm GGO)

Lesion Location: Left Upper Lobe (LUL)

Visible on Fluoro: No

Lesion Density: This semi-solid lesion of -700 Hounsfield units (HU) 


Case Information

Full Procedure Time: 3 hours 6 minutes

Anesthesia Start: 10:53

Anesthesia Stop: 13:59

 

Final Pathology Report

TOTAL SIZE (invasive lepidic components): 1.2 cm

 INVASIVE TUMOR SIZE: 0.5 cm

HISTOLOGIC TYPE: Adenocarcinoma, lepidic predominant pattern


Patient Background

77-year-old male with PMH of CHF, HTN, CAD s/p CABG, and stent placement. 40-pack year smoking history. GERD presents for follow-up of repeat CT Chest. The patient's breathing has improved with inhalers. The patient underwent CT of the chest which demonstrated increased progression of LUL ground glass opacities now with some semi-solid lesions. 

 

Chest CT showed a 15.2 mm ground-glass opacity (GGO) with two small 1-2 mm nodular solid components in the left upper lobe slightly increased in size and the nodules are new.




Lesion Marking

LungVision’s proprietary artificial intelligence (AI)-driven imaging algorithm intraoperatively generates near-CT quality scans from X-ray images acquired during a C-arm spin. This enabled the visualization and precise dye marking of a semi-solid lesion that had a GGO component of -700 Hounsfield units (HU).


Intraoperative visualization of the GGO under LungVisionTM C-Arm Based Tomography (CABT) imaging.


Dye Marking for Resection

Under LungVision’s real-time augmented fluoroscopy, an indocyanine green (ICG)-soaked coil was placed into the lesion to dye mark the lesion for a subsequent resection.


Placement of ICG-soaked coil to dye mark lesion for subsequent resection under LungVisionTM real-time augmented fluoroscopy. 


When the specimen was brought to the pathologist, it was not palpable, and the pathologist deferred to formalin fixation for definitive diagnosis (permanent specimen). 


Final Pathology 

SPECIMEN TYPE AND PROCEDURE:  Wedge resection

LATERALITY: Left

TUMOR SITE: Upper lobe

SPECIMEN INTEGRITY: Intact

TUMOR FOCALITY: Unifocal

TUMOR SIZE:

 TOTAL SIZE (invasive lepidic components): 1.2 cm

 INVASIVE TUMOR SIZE: 0.5 cm

HISTOLOGIC TYPE: Adenocarcinoma, lepidic predominant pattern

HISTOLOGIC GRADE: Not applicable

VISCERAL PLEURAL INVASION: None

TUMOR EXTENSION: Confined to lung


This patient is scheduled for a Robotic Trisegmentectomy/Possible Lobectomy and Mediastinal Lymph Node Dissection in 2 weeks.


Conclusion

LungVisionTM intraoperative CT imaging provided real-time imaging of this semi-solid lesion in order to enable the accurate dye marking needed for resection of the suspicious pulmonary lesion for both diagnosis and treatment in a single-anesthesia event.


About Dr. Tsai

Wilson Tsai, MD

Director, Thoracic Surgical Program

John Muir Health

United States
Address
Body Vision Medical Inc. 900 E. Hamilton Avenue, Suite 210 Campbell, California 95008 US: +1 888-302-5439 International: 603-267-3962
Contact Body Vision Medical
Get in touch with us for information about acquiring LungVision™, the latest product updates, company news and more. A member of our team will be in touch shortly.
First Name
Last Name
Email
Phone Number
Country
Position / Job Title
Organization / Company
Message